FDA deems Sanofi/Genzyme drug olipudase alfa 'breakthrough'
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation (BTD) to an experimental medicine from Sanofi and its US Genzyme unit for olipudase alfa, an experimental enzyme replacement therapy being investigated to treat Niemann-Pick disease type B (NPB).